Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.64 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.61 |
| ▸ | GABRD | O14764 | 2/20 | 0.61 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.61 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.61 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.61 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.61 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.61 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.61 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.61 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.56 |
| ▸ | NAMPT | P43490 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14742135 | 0.91 | NAMPT (0.66) | L3MBTL3L3MBTL1SIGMAR1GABRDGABRA1 | |
| SCHEMBL6634743 | 0.91 | HSD17B10 (0.60) | L3MBTL3L3MBTL1SIGMAR1GABRDGABRA1 | |
| SCHEMBL5436686 | 0.91 | GABRD (0.73) | SIGMAR1GABRDGABRA1GABRB1GABRA5 | |
| SCHEMBL21078285 | 0.86 | NAMPT (0.64) | L3MBTL3L3MBTL1SIGMAR1GABRDGABRA1 | |
| SCHEMBL16565827 | 0.85 | GABRD (0.84) | L3MBTL3L3MBTL1GABRDGABRA1GABRB1 | |
| SCHEMBL7170182 | 0.85 | NAMPT (0.65) | SIGMAR1GABRDGABRA1GABRB1GABRA5 | |
| SCHEMBL7170178 | 0.83 | NAMPT (0.67) | L3MBTL3L3MBTL1SIGMAR1NAMPT | |
| SCHEMBL6631344 | 0.83 | HSD17B10 (0.67) | L3MBTL3L3MBTL1SIGMAR1NAMPT | |
| SCHEMBL17888472 | 0.82 | GABRD (0.61) | L3MBTL3L3MBTL1GABRDGABRA1GABRB1 | |
| SCHEMBL21078072 | 0.82 | GABRD (0.61) | L3MBTL3L3MBTL1GABRDGABRA1GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0854869-B1 | SPIRO COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION | LILLY CO ELI (US) | 2004-08-25 | — | — | EP | disclosed |
| US-6528534-B2 | Useful as glycoprotein IIb/IIIa antagonists for prophylaxis thrombosis, therapy of atheroschlerosis, arterioschlerosis, acute myocardial infarction, chronic stable angina, unstable angina, transient ischemic attacks and strokes | MILLENNIUM PHARMACEUTICALS, INC. | 2003-03-04 | — | — | US | disclosed |
| US-20020013325-A1 | Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation | FISHER MATTHEW J (US) | 2002-01-31 | — | — | US | disclosed |
| US-6291469-B1 | Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation | ELI LILLY AND COMPANY | 2001-09-18 | — | — | US | disclosed |
| EP-0854869-A1 | SPIRO COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION | ELI LILLY AND COMPANY (US) | 1998-07-29 | — | — | EP | disclosed |
| WO-1997011940-A1 | SPIRO COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION | ELI LILLY AND COMPANY (US) | 1997-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013325-A1 | Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation | PF4, PFKP, SELP | L3MBTL3 4859/4885L3MBTL1 4735/4885SIGMAR1 4236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.